{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:55:12Z","timestamp":1787162112668,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hereditary breast and ovarian cancer has long been established to affect a considerable number of patients and their families. By identifying those at risk ideally before they have been diagnosed with breast and\/or ovarian cancer, access to preventive measures, intensified screening and special therapeutic options can be obtained, and thus, prognosis can be altered beneficially. Therefore, a standardized screening and counseling process has been established in Germany under the aegis of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). As one of these specialized clinics, the HBOC-Center at Charit\u00e9 offers genetic counseling as well as genetic analysis based on the GC-HBOC standards. This analysis aims first at depicting this process from screening through counseling to genetic analysis as well as the patient collective and second at correlating the results of genetic analysis performed. Thus, real-world data from an HBOC-Center with a substantial patient collective and a high frequency of pathogenic variants in various genes shall be presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The data of 2531 people having been counseled at the HBOC-Center at Charit\u00e9 in 2016 and 2017 were analyzed in terms of patient and family history as well as pathogenic variants detected during genetic analysis with the TruRisk\n                      <jats:sup>\u00ae<\/jats:sup>\n                      gene panel when genetic analysis was conducted. This standardized analysis is compiled and regularly adjusted by the GC-HBOC. The following genes were included at time of research:\n                      <jats:italic>BRCA1, BRCA2, ATM, CDH1, CHEK2, PALB2, RAD51C, RAD51D, NBN,<\/jats:italic>\n                      and\n                      <jats:italic>TP53.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Genetic analysis was conducted in 59.8% of all cases meeting the criteria for genetic analysis and 286 pathogenic variants were detected among 278 (30.3%) counselees tested using the TruRisk\n                      <jats:sup>\u00ae<\/jats:sup>\n                      gene panel. These were primarily found in the genes\n                      <jats:italic>BRCA1<\/jats:italic>\n                      (44.8%) and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      (28.3%) but also in\n                      <jats:italic>CHEK2<\/jats:italic>\n                      (12.2%),\n                      <jats:italic>ATM<\/jats:italic>\n                      (5.6%) and\n                      <jats:italic>PALB2<\/jats:italic>\n                      (3.5%). The highest prevalence of pathogenic variants was seen among the families with both ovarian and breast cancer (50.5%), followed by families with ovarian cancer only (43.2%) and families with breast cancer only (35.6%)\u2014these differences are statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Considering breast cancer subtypes, the highest rate of pathogenic variants was detected among patients with triple-negative breast cancer (40.7%) and among patients who had had been diagnosed with triple-negative breast cancer before the age of 40 (53.4%)\u2014both observations proved to be statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Genetic counseling and analysis provide the foundation in the prevention and therapy of hereditary breast and ovarian cancer. The rate of pathogenic variants detected is associated with family history as well as breast cancer subtype and age at diagnosis, and can reach considerable dimensions. Therefore, a standardized process of identification, genetic counseling and genetic analysis deems mandatory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-022-06819-3","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T13:05:26Z","timestamp":1666962326000},"page":"1585-1592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center"],"prefix":"10.1007","volume":"307","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9951-149X","authenticated-orcid":false,"given":"Benedikt","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malina","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Besch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Kalmbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Stegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"6819_CR1","volume-title":"Regional office for Europe, world cancer report: cancer research for cancer development","author":"World Health Organization","year":"2020","unstructured":"World Health Organization (2020) Regional office for Europe, world cancer report: cancer research for cancer development. Place of publication not identified: IARC"},{"key":"6819_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954","author":"Y Miki","year":"1994","unstructured":"Miki Y et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. https:\/\/doi.org\/10.1126\/science.7545954","journal-title":"Science"},{"issue":"6559","key":"6819_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789\u2013792. https:\/\/doi.org\/10.1038\/378789a0","journal-title":"Nature"},{"issue":"26","key":"6819_CR4","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer\u201c. J Clin Oncol Off J Am Soc Clin Oncol 26(26):4282\u20134288. https:\/\/doi.org\/10.1200\/JCO.2008.16.6231","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6819_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3829","author":"DG Evans","year":"2013","unstructured":"Evans DG, Graham J, O\u2019Connell S, Arnold S, Fitzsimmons D (2013) Familial breast cancer: summary of updated NICE guidance. BMJ. https:\/\/doi.org\/10.1136\/bmj.f3829","journal-title":"BMJ"},{"key":"6819_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1376","author":"J Hauke","year":"2018","unstructured":"Hauke J et al (2018) Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.1376","journal-title":"Cancer Med"},{"key":"6819_CR7","doi-asserted-by":"publisher","DOI":"10.1055\/a-0574-4879","author":"A Waha","year":"2018","unstructured":"Waha A et al (2018) Konsensusempfehlung des Deutschen Konsortiums Famili\u00e4rer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse. Tumordiagn Ther. https:\/\/doi.org\/10.1055\/a-0574-4879","journal-title":"Tumordiagn Ther"},{"key":"6819_CR8","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5060","author":"K Lagerstedt-Robinson","year":"2016","unstructured":"Lagerstedt-Robinson K et al (2016) Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2016.5060","journal-title":"Oncol Rep"},{"key":"6819_CR9","volume-title":"Ataxia telangiectasia","author":"GM Riboldi","year":"2022","unstructured":"Riboldi GM, Samanta D, Frucht S (2022) Ataxia telangiectasia. StatPearls publishing, StatPearls"},{"key":"6819_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/genes12101520","author":"ER Woodward","year":"2021","unstructured":"Woodward ER, Meyer S (2021) Fanconi anaemia, childhood cancer and the BRCA genes. Genes. https:\/\/doi.org\/10.3390\/genes12101520","journal-title":"Genes"},{"issue":"2","key":"6819_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ygyno.2013.11.030","volume":"132","author":"U Menon","year":"2014","unstructured":"Menon U, Griffin M, Gentry-Maharaj A (2014) Ovarian cancer screening\u2013current status, future directions. Gynecol Oncol 132(2):490\u2013495. https:\/\/doi.org\/10.1016\/j.ygyno.2013.11.030","journal-title":"Gynecol Oncol"},{"key":"6819_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24038","author":"NM van der Velde","year":"2009","unstructured":"van der Velde NM et al (2009) Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers?\u201c. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.24038","journal-title":"Int J Cancer"},{"key":"6819_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05152-9","author":"U Bick","year":"2019","unstructured":"Bick U et al (2019) High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-019-05152-9","journal-title":"Breast Cancer Res Treat"},{"key":"6819_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.21.1633","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/93.21.1633","journal-title":"J Natl Cancer Inst"},{"key":"6819_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.188","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2004.04.188","journal-title":"J Clin Oncol"},{"key":"6819_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05345-2","author":"BAM Heemskerk-Gerritsen","year":"2019","unstructured":"Heemskerk-Gerritsen BAM et al (2019) Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-019-05345-2","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6819_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.pec.2019.05.007","volume":"102","author":"D Speiser","year":"2019","unstructured":"Speiser D, Rebitschek FG, Feufel MA, Brand H, Besch L, Kendel F (2019) Accuracy in risk understanding among BRCA1\/2-mutation carriers. Patient Educ Couns 102(10):1925\u20131931. https:\/\/doi.org\/10.1016\/j.pec.2019.05.007","journal-title":"Patient Educ Couns"},{"key":"6819_CR18","unstructured":"\u201ccheckliste_erbliche-belastung_brust_gyn\u201d (2022) \u00c4rztekammer Westfalen-Lippe, Deutsche Krebsgesellschaft, Deutsche Gesellschaft f\u00fcr Senologie und Deutsches Konsortium f\u00fcr famili\u00e4ren Brust- und Eierstockkrebs. Zugegriffen: 22 M\u00e4rz 2022. [Online]. Verf\u00fcgbar unter: https:\/\/www.krebsgesellschaft.de\/zertdokumente.html"},{"key":"6819_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103672","author":"K Kast","year":"2016","unstructured":"Kast K et al (2016) Prevalence of BRCA1\/2 germline mutations in 21\u2005401 families with breast and ovarian cancer. J Med Genet. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103672","journal-title":"J Med Genet"},{"key":"6819_CR20","unstructured":"GC-HBOC (2019) GC-HBOC. Erkennung von Genver\u00e4nderungen durch einen Gentest\u201c, downloaded on 9 May 2019. https:\/\/www.konsortium-familiaerer-brustkrebs.de\/informationen\/gentest-einschlusskriterien\/"},{"key":"6819_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20880","author":"SE Plon","year":"2008","unstructured":"Plon SE et al (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. https:\/\/doi.org\/10.1002\/humu.20880","journal-title":"Hum Mutat"},{"key":"6819_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177893","author":"C Evers","year":"2017","unstructured":"Evers C, Fischer C, Dikow N, Schott S (2017) Familial breast cancer: genetic counseling over time, including patients\u00b4 expectations and initiators considering the Angelina Jolie effect. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0177893","journal-title":"PLoS ONE"},{"key":"6819_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2472-1","author":"C Staudigl","year":"2016","unstructured":"Staudigl C et al (2016) Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the, Angelina Jolie Effect. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-016-2472-1","journal-title":"BMC Cancer"},{"issue":"8","key":"6819_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1586\/14737140.6.8.1205","volume":"6","author":"JI Goldberg","year":"2006","unstructured":"Goldberg JI, Borgen PI (2006) Breast cancer susceptibility testing: past, present and future. Expert Rev Anticancer Ther 6(8):1205\u20131214. https:\/\/doi.org\/10.1586\/14737140.6.8.1205","journal-title":"Expert Rev Anticancer Ther"},{"key":"6819_CR25","unstructured":"Schroeder C, Faust U, Sturm M, Hackmann K, Grundmann K, Harmuth F, Bosse K, Kehrer M, Benkert T, Klink B, Mackenroth L, Betcheva-Krajcir E, Wimberger P, Kast K, Heilig M, Nguyen HP, Riess O, Schr\u00f6ck E, Bauer P, Rump A (2009) HBOC multi-gene panel testing: comparison of two sequencing centers. https:\/\/hero.epa.gov\/hero\/index.cfm\/reference\/details\/reference_id\/3150057 (Zugegriffen 20 Feb 2022)"},{"key":"6819_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4330-z","author":"C Meisel","year":"2017","unstructured":"Meisel C et al (2017) Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. Arch Gynecol Obstet. https:\/\/doi.org\/10.1007\/s00404-017-4330-z","journal-title":"Arch Gynecol Obstet"},{"key":"6819_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3429-9","author":"C Schroeder","year":"2015","unstructured":"Schroeder C et al (2015) HBOC multi-gene panel testing: comparison of two sequencing centers. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-015-3429-9","journal-title":"Breast Cancer Res Treat"},{"key":"6819_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RG (2019) A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 11:543\u2013561. https:\/\/doi.org\/10.2147\/CLEP.S206949","journal-title":"Clin Epidemiol"},{"key":"6819_CR29","doi-asserted-by":"publisher","DOI":"10.1159\/000455999","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK (2017) Germline mutations in triple-negative breast cancer. Breast Care Basel Switz. https:\/\/doi.org\/10.1159\/000455999","journal-title":"Breast Care Basel Switz"},{"key":"6819_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"6819_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl947","author":"C Capalbo","year":"2006","unstructured":"Capalbo C et al (2006) BRCA1 and BRCA2 genetic testing in Italian breast and\/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models\u201c. Ann Oncol Off J Eur Soc Med Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdl947","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"6819_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1480","author":"TS Frank","year":"2002","unstructured":"Frank TS et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals\u201c. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2002.20.6.1480","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6819_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-140","author":"E Machackova","year":"2008","unstructured":"Machackova E et al (2008) Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and\/or ovarian cancer. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-8-140","journal-title":"BMC Cancer"},{"key":"6819_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1414","author":"FJ Couch","year":"2015","unstructured":"Couch FJ et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2014.57.1414","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6819_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4029-y","author":"C Engel","year":"2018","unstructured":"Engel C et al (2018) Prevalence of pathogenic BRCA1\/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-018-4029-y","journal-title":"BMC Cancer"},{"key":"6819_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.1090","author":"K Rhiem","year":"2016","unstructured":"Rhiem K et al (2016) BRCA1\/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.1090","journal-title":"J Clin Oncol"},{"issue":"2","key":"6819_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00404-017-4631-2","volume":"297","author":"K Kast","year":"2018","unstructured":"Kast K, Wimberger P, Arnold N (2018) Changes in classification of genetic variants in BRCA1 and BRCA2. Arch Gynecol Obstet 297(2):279\u2013280. https:\/\/doi.org\/10.1007\/s00404-017-4631-2","journal-title":"Arch Gynecol Obstet"},{"key":"6819_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2013.181","author":"DLG Borzekowski","year":"2014","unstructured":"Borzekowski DLG, Guan Y, Smith KC, Erby LH, Roter DL (2014) The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med Off J Am Coll Med Genet. https:\/\/doi.org\/10.1038\/gim.2013.181","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"6819_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.007","author":"CF Singer","year":"2019","unstructured":"Singer CF et al (2019) Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. Eur J Cancer Oxf Engl. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.007","journal-title":"Eur J Cancer Oxf Engl"},{"key":"6819_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-016-9900-x","author":"AS Jacobs","year":"2016","unstructured":"Jacobs AS et al (2016) Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast\/ovarian cancer. Fam Cancer. https:\/\/doi.org\/10.1007\/s10689-016-9900-x","journal-title":"Fam Cancer"},{"key":"6819_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.3226","author":"MD Schwartz","year":"2014","unstructured":"Schwartz MD et al (2014) Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2013.51.3226","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06819-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T13:08:34Z","timestamp":1681736914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06819-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["6819"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06819-3","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval was granted by the Ethics Committee of Charit\u00e9 Universit\u00e4tsmedizin (EA2\/144\/18).\u201d","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}